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Abstract
Background: The objective was to evaluate the safety and immunogenicity of the AMA1-based malaria vaccine FMP2.1/
AS02A in children exposed to seasonal falciparum malaria.
Methodology/Principal Findings: A Phase 1 double blind randomized controlled dose escalation trial was conducted in
Bandiagara, Mali, West Africa, a rural town with intense seasonal transmission of Plasmodium falciparum malaria. The malaria
vaccine FMP2.1/AS02A is a recombinant protein (FMP2.1) based on apical membrane antigen 1 (AMA1) from the 3D7 clone
of P. falciparum, formulated in the Adjuvant System AS02A. The comparator vaccine was a cell-culture rabies virus vaccine
(RabAvertH). One hundred healthy Malian children aged 1–6 years were recruited into 3 cohorts and randomized to receive
either 10 mg FMP2.1 in 0.1 mL AS02A, or 25 mg FMP2.1 in 0.25 mL AS02A, or 50 mg FMP2.1 50 mg in 0.5 mL AS02A, or rabies
vaccine. Three doses of vaccine were given at 0, 1 and 2 months, and children were followed for 1 year. Solicited symptoms
were assessed for 7 days and unsolicited symptoms for 30 days after each vaccination. Serious adverse events were assessed
throughout the study. Transient local pain and swelling were common and more frequent in all malaria vaccine dosage
groups than in the comparator group, but were acceptable to parents of participants. Levels of anti-AMA1 antibodies
measured by ELISA increased significantly (at least 100-fold compared to baseline) in all 3 malaria vaccine groups, and
remained high during the year of follow up.
Conclusion/Significance: The FMP2.1/AS02A vaccine had a good safety profile, was well-tolerated, and induced high and
sustained antibody levels in malaria-exposed children. This malaria vaccine is being evaluated in a Phase 2 efficacy trial in
children at this site.
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Introduction
A safe and effective malaria vaccine would be a major addition
to current malaria control tools and could reinforce hope for
malaria eradication. The Plasmodium falciparum apical membrane
antigen 1 (AMA1) is considered to be a promising antigen for
blood stage vaccine development based on evidence that it plays a
critical role during merozoite invasion of erythrocytes and that this
function can be abrogated with inhibitory antibodies [1–5], and on
sero-epidemiological studies showing association of anti-AMA1
antibodies with naturally acquired protection against malaria
[6,7]. A vaccine that boosts levels of anti-AMA1 antibodies might
therefore reduce the risk that malaria infection will cause clinical
disease, making AMA1 an attractive candidate for inclusion in a
multi-stage, multi-antigen malaria vaccine [8].
AMA1 is highly polymorphic–more than 300 unique AMA1
haplotypes have been identified worldwide and more than 200 at a
single site in Mali [9]. This extreme genetic diversity presumably
results from balancing selection driven by host immunity. In vitro
[10] and animal studies [4,11,12] have suggested the possibility of
strain-specific immunity, raising concern that AMA1 vaccines
based on one or a few alleles might not provide broad protection
[13]. However, both in vitro [14] and molecular epidemiological
[9,15] studies have suggested possible diversity-covering approach-
es to developing effective AMA1 vaccines.
Three AMA1-based adjuvanted protein vaccines have been
evaluated in clinical trials in Mali, including two different
monovalent vaccines based on AMA1 derived from the 3D7 and
FVO clones of P. falciparum, respectively, [12,16,17] and a bivalent
vaccine that includes both the 3D7 and FVO versions of AMA1
adjuvanted with aluminum hydroxide [18–20]. The failure of this
bivalent AMA1 vaccine to protect children in a Phase 2 trial in
Mali [20] may be due to the relatively modest and short-lived
nature of the antibody responses generated by the vaccine and/or
to the inability to overcome genetic diversity.
FMP2.1 is a lyophilized preparation of the ectodomain of the
3D7 clone of P. falciparum AMA1 [21]. A Phase 1 study in malaria-
naı¨ve North American volunteers found that the AMA1-based
vaccine FMP2.1/AS02A elicited potent humoral and cellular
immune responses and that immune sera recognized sporozoites
and merozoites by immunofluorescence assay and inhibited both
parasite growth and AMA1 processing in homologous 3D7
parasites [16]. The first Phase 1 study of this vaccine in a
malaria-exposed population found it to have promising safety and
tolerability profiles in adults in Bandiagara, Mali, and to elicit
dose-dependent anti-AMA1 antibody responses [17] as well as IL-
5 production and lymphocyte proliferative responses [22].
The overall objective of the current study was to identify an
optimal pediatric dose of FMP2.1/AS02A that is safe, with high
immunogenicity and acceptable reactogenicity, for progression to
efficacy testing. The safety and reactogenicity of FMP2.1/AS02A,
as well as the magnitude and duration of the antibody response,
were evaluated in children naturally exposed to P. falciparum
infection.
Methods
The protocol and supporting CONSORT checklist are available
as supporting information; see Protocol S1 and Checklist S1.
Study Setting
The study was conducted at the Bandiagara Malaria Project
research clinic adjacent to the district hospital in Bandiagara, a
rural town of 13,634 inhabitants in the Dogon Country in
northeast Mali. Bandiagara is relatively dry, with a mean annual
rainfall of 600 mm. Anopheles gambiae is the principal malaria
vector. Malaria transmission is highly seasonal, with minimal
transmission at the height of the dry season in March; less than
one infected bite per person per month as the transmission season
starts and ends in June and December, respectively; and a peak of
up to 60 infected mosquito bites per person per month in August
or September [23,24]. P. falciparum represents 97% of malaria
infections with 3% due to P. malariae and rare infections with P.
ovale. Despite the seasonal transmission pattern, the malaria
burden is heavy: children aged less than 10 years have an average
of 2 clinical malaria episodes every transmission season [24], and
severe malaria afflicts 1 in 50 children aged less than 6 years each
year [23]. Older children and adults are relatively protected
against malaria disease, but remain susceptible to infection.
Participants
After obtaining community permission as described by Diallo
et al. [25], the trial was publicized by local radio broadcast.
Parents were invited to bring children aged 1 to 6 years to the
research clinic to be screened for eligibility. Children were eligible
for inclusion if they planned to remain in Bandiagara for at least
12 months and if their parents or guardians gave written informed
consent. Exclusion criteria included: significant current illness as
indicated by history, examination and/or laboratory testing
including complete blood counts, alanine aminotransferase
(ALT) and serum creatinine; previous immunization with a rabies
vaccine or any experimental vaccine; chronic use of immunosup-
pressants; receipt of blood products during the previous 6 months;
and allergy to substances present in the vaccines.
Ethics
The trial was conducted in compliance with the International
Conference on Harmonisation Good Clinical Practices, the
Declaration of Helsinki and regulatory requirements of Mali.
The protocol was approved by institutional review boards of the
University of Bamako Faculty of Medicine, University of
Maryland Baltimore, and the U.S. Army Surgeon General.
Separate written informed consent was obtained for screening
and enrollment. Verbal consent of illiterate parents or guardians
was administered and then documented using their thumbprints, a
process verified by signatures of independent witnesses. Permission
to import and administer the investigational products in Mali was
granted by the Republic of Mali Ministry of Health. The trial was
monitored by the National Institute of Allergy and Infectious
Diseases, Division of Microbiology and Infectious Diseases and the
United States Army Medical Material Development Activity.
Interventions
The FMP2.1 antigen (Lot 1046) is comprised of amino acids
#83-531 corresponding to the ectodomain of AMA1 derived from
the 3D7 clone of P. falciparum. The protein was produced in and
purified from E. coli bacteria under current Good Manufacturing
Practices (cGMP) at the Walter Reed Army Institute of Research
Pilot Bioproduction Facility (Forest Glen, Maryland, United
States) [21]. The vaccine was provided in vials containing
approximately 50 mg of lyophilized protein.
The AS02A Adjuvant System is composed of an oil-in-water
emulsion and 2 immuno-stimulants, 3-deacylated monopho-
sphoryl lipid A and QS21, a saponin agent derived from the soap
bark tree, Quillaja saponaria [26,27]. AS02A was manufactured by
GlaxoSmithKline Biologicals (Rixensart, Belgium) according to
cGMP and provided in pre-filled syringes. The whole content of
each FMP2.1 vial was dissolved by adding the contents of 0.62 mL
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pre-filled syringes of AS02A to the vial immediately before
injection, mixing well, and withdrawing into a new syringe. The
RabAvertH rabies vaccine (Chiron Corporation, Emeryville,
California, United States) is a sterile freeze-dried vaccine obtained
by growing the fixed-virus strain Flury LEP in primary cultures of
chicken fibroblasts. It is supplied in pre-filled syringes containing
lyophilized antigen to which 1 mL of sterile water was added as
diluent before injection. All doses of all vaccines were administered
by intramuscular injection preferably in the left deltoid muscle.
One hundred children aged 1 to 6 years were sequentially
assigned to 3 cohorts of 20, 40 and 40 participants with
stratification for age by 2-year increments (1–2 years, 3–4 years,
and 5–6 years) to ensure that the study groups were balanced by
age in case of age-related differences in tolerability or immuno-
genicity. Within each cohort, participants were randomized in a
3:1 fashion to receive 10, 25 or 50 mg of FMP2.1 adjuvanted
with a proportionate volume of AS02A, or rabies vaccine. After
reconstitution, the doses of FMP2.1/AS02A were approximately:
10 mg of FMP2.1 in a final volume of 0.10 mL AS02A in Cohort 1,
25 mg of FMP2.1 in a final volume of 0.25 mL AS02A in Cohort 2,
and 50 mg FMP2.1 in a final volume of 0.5 mL in Cohort 3.
Because the final injection volumes were slightly smaller than the
reconstitution volumes, the doses of the FMP2.1 antigen delivered
were slightly less than 10, 25 or 50 mg. Vaccines were given on a
0-, 1- and 2-month schedule. In each cohort, older children were
immunized at least one day before younger children so that
vaccine responses could be observed first in older children before
exposing younger children to potential risks of vaccination. The
first vaccination was given in early November 2006 near the end of
the peak malaria transmission season; the second and the third
doses were given in December - February 2007, when malaria
transmission typically declines to virtually undetectable levels at
this site. The final study follow-up visit on day 364 coincided with
the end of the 2007 malaria transmission season. The cohorts were
immunized in a staggered fashion to permit interim safety
analyses; each successive immunization of Cohort 1 was followed
in approximately 3 weeks by the corresponding immunization of
Cohort 2. Immunizations of Cohort 2 were followed in a similar
way by immunizations of Cohort 3. Two interim safety analyses
were reviewed by an independent Data and Safety Monitoring
Board, which provided written recommendations to proceed
before each of the first immunizations of Cohorts 2 and 3.
Objectives
The primary objective was to evaluate the safety and
reactogenicity of 3 injections of 3 different dose levels of the
malaria vaccine FMP2.1/AS02A in malaria-experienced Malian
children. The secondary objective was to measure the magnitude
and duration of antibody responses to FMP2.1. Exploratory
objectives include measuring vaccine-induced cellular immune
responses at baseline and after immunization (results to be
presented elsewhere).
Outcomes
The primary outcome was safety, measured as 1) occurrence of
solicited symptoms during a 7-day follow-up period after
immunization (day of immunization and days 1, 2, 3 and 7 after
immunization); 2) occurrence of unsolicited symptoms during a
30-day follow-up period after each immunization (day of
immunization and 29 subsequent days); and 3) occurrence of
serious adverse events (SAE) during the study period. Secondary
outcome measures include serum antibody levels and activity of
anti-FMP2.1 measured against recombinant 3D7 AMA1 at
baseline and at specified times during and after immunization.
Assessment of safety and tolerability. Following each
immunization, participants were directly observed for 60 minutes,
then evaluated at the study clinic 1, 2, 3, 7, 14 and 30 days after
each immunization and on study days 120, 180, 272 and 364.
Starting on day 180, monthly home visits were made to check the
health status of participants and to encourage parents or guardians
to bring them to the research clinic if they felt ill. Study physicians
were available at the research clinic at all times throughout the 12-
month study period to assess and treat adverse events.
Clinical evaluations consisted of measurement of vital signs and
assessment for local injection site and general solicited signs or
symptoms. Local signs and solicited symptoms included pain or
tenderness, swelling, and erythema at the injection site. General
signs and solicited symptoms included fever (oral temperature
$37.5uC), vomiting, irritability/fussiness, drowsiness and loss of
appetite. Any other signs or symptoms were considered to be
unsolicited, as were signs or symptoms that occurred more than 7
days after immunization. Solicited symptoms were considered to be
related to the study vaccines. Unsolicited signs and symptoms were
recorded during the 30 days after each immunization, whereas
SAEs were monitored throughout the 12-month study period.
Blood was collected at screening, on immunization days, 7 days
after each immunization and on study days 90, 180, 272 and 364
to determine complete blood count, ALT and serum creatinine.
Although clinical malaria episodes were not formally assessed as a
study endpoint, malaria microscopy was performed for diagnostic
purposes whenever participants presented with symptoms sugges-
tive of malaria.
Adverse events were graded by severity and judged for potential
association to study vaccines. Solicited adverse events were graded
according to the system outlined in Table 1. Other non-laboratory
adverse events were classified as grade 1–3 adverse events. Grade
1 adverse events were easily tolerated, causing minimal discomfort
and not interfering with daily activities. Grade 2 adverse events
were sufficiently discomforting to interfere with normal activities.
Grade 3 adverse events prevented normal daily activities. For
laboratory tests, toxicity grading was assigned using normal
reference ranges based on a similar local pediatric population
with the exception of absolute lymphocyte counts, which were
based on normal values in Ugandan children [28].
Antibody responses to AMA1. Antibody levels (mg/mL)
measuring total IgG against the P. falciparum 3D7 AMA1 vaccine
antigen were measured by an enzyme-linked immunosorbent
assay (ELISA) [16]. Briefly, plates were coated overnight at 4uC
with the FMP2.1 recombinant AMA1 antigen (100 mL/well,
0.5 mg/mL), after which they were blocked with a 0.5% boiled
casein buffer for 1 hour at 22uC. Test samples were added to the
plate, serially diluted in 8 sequential 2-fold serial dilutions (done in
triplicate) and incubated for 2 hours at 22uC. Secondary antibody
(Affinity Purified Antibody Peroxidase Labeled Goat Anti-Human
IgG (c), KPL, Gaithersburg, Maryland, United States: Cat#074-
1002) at a 1:4,000 dilution, was added and incubated for 1 hour at
22uC, after which substrate (ABTS Peroxidase Substrate System
(2-Component), KPL: Cat#50-62-01) was added and incubated
for an additional hour at 22uC. A stop solution (20% SDS) was
added and the plates were read using a Spectromax 340PC Plate
Reader (Molecular Devices, Sunnyvale, California, United States).
Between each incubation step the wells were washed in PBS using
a SkanWasher Plate Washer (Molecular Devices) with four
washing cycles of 400 ml each. Antibody responses were
measured on serum obtained from participants at the time of
each immunization (study days 0 [baseline], 30 and 60), and 1, 4, 7
and 10 months after the scheduled time of the last immunization
(study days 90, 180, 272 and 364).
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Sample Size
The sample size of 15 in the 10 mg dose group and 30 each in
the 25 mg and 50 mg dose groups was chosen to balance the need
to detect any possible untoward reactions against the need to limit
the number of volunteers exposed to an experimental vaccine for
evaluation of safety. This Phase 1 trial was thus not powered to
detect differences between groups. We used a comparator vaccine
group of 25 to permit broad estimates of the incidence of local and
general side effects and of immune responses among vaccine
recipients compared to controls. We began with a group of 20
children randomized 3:1 to receive 10 mg of FMP2.1 in 0.1 mL of
AS02A or rabies vaccine to rule out a common adverse reaction in
children that would preclude further testing. This was not
considered a dose level to be evaluated for further clinical
development and thus did not warrant the larger sample size of the
25 mg and 50 mg dose level groups.
Randomization—Sequence Generation
Participants were randomized to one of 3 cohorts in the order of
enrollment, with stratification for age by 2-year increments (1–2
years, 3–4 years, 5–6 years). Within each of the 3 cohorts, individual
participants were randomized in a 3:1 ratio to receive either
FMP2.1/AS02A or rabies vaccine. The randomization sequence was
generated by a computer program to ensure a 3:1 ratio of vaccine
allocation. Randomly generated sequential codes linked each study
number to a vaccine assignment (FMP2.1/AS02A or rabies vaccine).
Randomization—Allocation Concealment
The randomization sequence was provided by the study
statistician in an opaque sealed envelope to the study pharmacists.
In addition the local safety monitor was provided with a sealed
envelope to be opened if it was deemed necessary to determine
urgently the intervention a participant had received; no such
emergency unblinding occurred. The only people at the study site
with access to the randomization codes during the study were the 2
study pharmacists, who had no contact with study participants and
did not reveal vaccine assignments to anyone else. Study
participants and investigators who assessed outcomes were blinded
to vaccine assignment.
Randomization—Implementation
Clinical investigators assigned study numbers to participants of
each group in the order in which they arrived at the clinic on the
first day of immunization. On this day, study pharmacists opened
the sealed envelope containing the vaccine assignments and
prepared the vaccine to be administered to the respective study
participant. The vaccine and dose assigned during the first
immunization were maintained for second and third immuniza-
tions. The study pharmacists prepared the vaccines in a special
room with access strictly limited to them and to study monitors.
Syringes containing the prepared vaccines were passed through
small sliding doors from the vaccine preparation room to separate,
private vaccine administration rooms, where the immunizations
were administered.
Blinding
The reconstituted rabies vaccine was a clear to slightly opaque,
colorless suspension of 1 mL volume, while FMP2.1/AS02A was
off-white and 0.10, 0.25 or 0.5 mL in volume. Syringes containing
vaccines were covered with opaque tape to conceal their contents
from participants and immunizers. The study pharmacists, who
were unblinded, had no study-related contact with participants
and were not involved in outcome assessment. Because of the
difference in volumes, the immunizers could potentially have
deduced which vaccine was given to a specific participant, and
therefore they did not participate in other study procedures,
including follow-up assessments. The presence of both study
Table 1. Assessment of Solicited Adverse Event (AE) Intensity.
Solicited AE Grade Intensity Definition
Pain/tenderness at injection
site
0 Absent
1 Minor reaction to touch
2 Cries/protests on touch
3 Cries when limb is moved/
spontaneously painful
Swelling at injection site 0 Absent
1 ,5 mm
2 5–20 mm
3 .20 mm
Erythema at injection site 0 Absent
1 ,5 mm
2 5–20 mm
3 .20 mm
Limitation of arm motion/
shoulder abduction
0 None
1 .90u but ,120u
2 .30u but #90u
3 #30u
Fever 0 ,37.5uC
1 37.5–38.0uC
2 38.1–39.0uC
3 .39.0uC
Irritability/fussiness 0 Behavior as usual
1 Crying more than usual/no effect on
normal activity
2 Crying more than usual/interferes
with normal activity
3 Crying that cannot be comforted/
prevents normal activity
Drowsiness 0 Behavior as usual
1 Drowsiness easily tolerated
2 Drowsiness that interferes with
normal activity
3 Drowsiness that prevents normal
activity
Loss of appetite 0 Normal
1 Eating less than usual/no effect on
normal activity
2 Eating less than usual/interferes
with normal activity
3 Not eating at all
Vomiting 0 Absent
1 Occasional but able to eat/drink
normal amounts
2 Repeated with limited oral intake
3 Continuous, unable to keep down
liquids or solids
doi:10.1371/journal.pone.0009041.t001
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pharmacists and immunizers at the site was limited to the periods
during which immunizations were given, and these individuals did
not discuss vaccine allocation with other study staff.
Statistical Methods
Statistical analyses were performed using SAS version 9.2 (SAS,
Cary, North Carolina, United States). Confidence intervals for
geometric mean AMA1 antibody levels (mg/mL) were estimated by
using log10-transformed values, calculating the 95% confidence
interval based on the normal distribution, and then converting the
limits to the original scale for presentation. T-tests were used to
compare log-transformed antibody levels at each study time point.
Longitudinal mixed models were also used to estimate the effect of
vaccine dose on mean log-transformed antibody levels over time,
using a spatial exponential covariance structure to model the
correlation between measurements from the same individual while
taking into account the number of study days between measurements.
Safety and immunogenicity analyses were based on intention-to-treat,
such that all available data were included in analyses.
Results
Participant Flow
Three hundred and one (301) children were screened, and 100
who fulfilled the criteria for inclusion were enrolled in the study
(Figure 1). The most common reasons for exclusion were medical
illnesses such as anemia, respiratory infections and malaria. Nine
parents of screened children subsequently declined to allow their
children to participate in the study. In Cohort 1, one participant
missed the third vaccine dose due to an episode of anemia. In
Cohort 2, the third dose was not given to 5 children due to: hepatitis
B infection in one child, hepatitis A infections in 3 children and a
new asymptomatic systolic heart murmur in another child, further
assessments of whom uncovered no evidence of cardiac disease. In
Cohort 3, one child had hepatitis A and was not given the third
vaccine dose. In the same cohort, 2 children missed the second and
third vaccine doses, in one case because of anemia diagnosed on the
day that the second dose was due, and in the other case, because the
participant’s father withdrew consent for blood collection after first
vaccination. Children who missed vaccine doses continued to be
followed throughout the duration of the study.
Recruitment and Surveillance
Participants were recruited between October 28 and November
30, 2006. Immunizations for Cohort 1 began on November 3,
2006, for Cohort 2 on November 23, 2006, and for Cohort 3 on
December 13, 2006. Subsequent immunizations were done at 30-
day intervals following this staggered start. Active surveillance of
participants for 30 days after each immunization was completed in
March 2007, corresponding to study day 90. The database was
locked for the primary unblinded analysis after study day 90 so
that results could be used to plan a Phase 2 trial, and the study
continued in a single-blinded fashion, although individual study
allocations were not disclosed to on-site study investigators or staff,
with the exception of the principal investigator. The extended
surveillance phase included continuous free access to basic medical
care at the research clinic, monthly home visits, and scheduled
visits on study days 180, 272 and 364. Of the 100 children
enrolled, 96 completed the follow-up schedule.
Baseline Data
The four study groups were similar at enrollment with regard to
gender, age or laboratory parameters (Table 2). Forty-nine of 100
participants were female.
Numbers Analyzed
All available data from all participants, including partial data
from participants lost to follow-up, were included in both safety
and immunogenicity analyses.
Safety and Reactogenicity
Local solicited adverse events. Injection site swelling and
pain were the most common local solicited adverse events reported
during the 7 day post-immunization period (Tables 3 and 4). The
study was not powered for statistical comparisons of event rates
between groups, but the frequency and severity of these local
events tended to decrease with successive immunizations,
especially in the 10 mg group. The proportion of children who
experienced local pain or swelling was higher in the malaria
vaccine groups compared to the rabies vaccine group. Grade 3
local adverse events consisted mainly of injection site swelling
(Figure 2), which was reported in all study groups, but had a
higher frequency in the 50 mg malaria vaccine group. Grade 3
local swelling was generally associated with minor injection site
pain. Other grade 3 local reactions consisted of injection site pain
and erythema. Grade 3 pain was always associated with grade 3
injection site swelling. One participant experienced grade 3 local
erythema that was associated with grade 3 injection site swelling
with no report of local pain.
Overall, the lowest proportion of children (80%) having at least
one local adverse event was observed in the 10 mg group among
the younger children aged 1–2 years. All local solicited adverse
events resolved without sequelae during the 7-day post-immuni-
zation periods.
Systemic solicited adverse events. Fever was the most
common systemic adverse event observed and was more frequent
in malaria vaccine recipients (Tables 3 and 4). The highest
proportion of children with fever was observed in the 25 mg group,
in which 30% of children had fever of mild to moderate intensity
after immunization 1. The proportion of children reporting at least
one systemic adverse event was the lowest among those aged 1–2
years and 5–6 years. Children in the 10 mg malaria vaccine and
the rabies vaccine groups experienced the fewest systemic adverse
events. All systemic solicited symptoms were of Grade 1 or Grade
2 intensity and all resolved during the 7-day follow-up period.
Unsolicited adverse events. Overall, 1,131 unsolicited
adverse events were reported during the 30-day post
immunization period. Unsolicited adverse events were balanced
by study groups and were representative of local patterns of
childhood illnesses. The majority of unsolicited symptoms for all
age groups were acute respiratory tract infections, followed by
malaria episodes and gastrointestinal disorders. Three unsolicited
adverse events were graded as severe; all were instances of
abnormal laboratory values in children aged 1–2 years old. A
white blood cell (WBC) count of 17.76103/mL was detected on the
day of the first immunization (prior to immunization) with the
10 mg dose of the malaria vaccine, and a WBC of 22.66103/mL
was detected in another child 1 week after the first rabies vaccine
immunization. Both of these elevated WBC counts were associated
with concurrent minor infections. In the third case, a serum ALT
of 364 U/L that was detected 1 week after the third immunization
with the 50 mg dose of the malaria vaccine was determined to be
due to hepatitis A infection, confirmed by serology. All abnormal
lab values resolved within 1 month.
Serious adverse events. Four serious adverse events (SAE)
occurred during the study. The first was a WBC elevation to
30.36103/mL (defined according to the protocol as an SAE) that
was detected 1 week after the second immunization with the 10 mg
malaria vaccine. This leukocytosis occurred contemporaneously
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Figure 1. Trial profile.
doi:10.1371/journal.pone.0009041.g001
Table 2. Baseline Characteristics of FMP2.1/AS02A and Rabies Vaccine groups.
Characteristics FMP2.1/AS02A 10 mg FMP2.1/AS02A 25 mg FMP2.1/AS02A 50 mg Rabies Vaccine
n=15 n=30 n=30 n=25
Mean age in year (SD) 3.5 (1.8) 3.5 (1.7) 3.6 (1.7) 3.2 (1.9)
Number of Females (%) 7 (46.7) 15 (50.0) 12 (40.0) 15 (60.0)
Mean WBC x 103/mL (SD) 9.47 (3.67) 8.83 (2.20) 9.53 (2.59) 9.62 (3.02)
Mean hemoglobin g/dL (SD) 10.9 (1.2) 11.0 (1.0) 11.0 (1.1) 10.6 (0.8)
Mean platelets x 103/mL (SD) 448 (129) 422 (152) 410 (151) 423 (132)
Mean lymphocytes x 103/mL (SD) 5.03 (2.02) 4.84 (1.64) 4.75 (1.75) 5.26 (1.96)
Mean creatinine mM/L (SD) 44.1 (0.0) 44.1 (0.0) 44.3 (1.3) 44.1 (0.0)
Mean ALT U/L (SD) 13.53 (5.34) 20.10 (21.82) 18.23 (8.55) 15.44 (6.92)
GMT Anti-AMA-1 antibody titer 532 500 1,088 456
(95% CI) (97-2,922) (168-1,489) (448-2,645) (151-1,377)
GMT, geometric mean titer; CI, confidence interval; ALT, alanine aminotransferase; SD, standard deviation.
doi:10.1371/journal.pone.0009041.t002
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with a malaria illness episode and resolved shortly after the end of
the malaria episode. The second SAE was an elevation of serum
ALT to grade 4 toxicity level at 521 U/L that was detected 1 week
after receipt of the second dose of rabies vaccine. The high value
was detected at a scheduled clinic visit and was not associated with
any concerning clinical symptoms. Serological testing identified
hepatitis A infection as the cause of the elevated ALT, which
returned to normal after 2 weeks. Nevertheless the third
immunization was withheld. The third and fourth SAEs were
both ALT elevations that occurred in children with minor clinical
symptoms and were determined by serological testing to be caused
by a hepatitis B infection. In the first case, a moderate ALT
elevation to 53 U/L was reported after the third immunization
with the 25 mg dose of malaria vaccine. Thirty days later the ALT
level was 1,260 U/L, constituting grade 4 toxicity and an SAE.
Given the temporal relationship with vaccination an association
cannot be ruled out, in that even with hepatitis B infection as the
primary cause of ALT elevation, vaccination could have amplified
the rise of ALT. The second case of hepatitis B occurred with a
rise in ALT to 1,371 U/L on study day 90, a month after all 3
rabies vaccine immunizations had been completed, and was
deemed not related to study products. All 4 SAEs resolved within 3
to 4 weeks of follow up with no sequelae.
Laboratory safety tests. Grade 1 elevated platelet count
was the most common laboratory abnormality and was observed
in 8, 16, 12 and 15 children in the 10 mg, 25 mg 50 mg and rabies
vaccine groups, respectively. The highest platelet counts were
reported in a 10 mg malaria vaccine recipient, with values of
1,0966103/mL on the day of the second immunization (prior to
immunization) and 1,3976103/mL a week after the second
immunization. These values were observed 5 weeks apart, with
a normal platelet count in between. This child experienced several
concurrent illnesses, including the SAE with very high WBC, and
was not given the third vaccine dose due to moderate anemia.
Hemoglobin levels remained within or slightly above the normal
range (9.8 g/dL to 12.4) for all but 4 participants throughout the
study. Four children had grade 1 low hemoglobin levels measured
at limited time points, one in the 10 mg group a week after the
second immunization; and 3 in the 25 mg group occurring on the
days of the first and second immunizations and a month after the
third immunization, respectively. One grade 2 low hemoglobin
was recorded in the 50 mg group on the day of the second
Figure 2. Grade 3 injection site swelling 1–2 days following immunization with the malaria vaccine. Injection site swelling was
considered grade 3 if it exceeded 20 mm in its widest dimension. Grade 3 swelling was typically unnoticed by participants and parents and came to
attention only during physical examinations. It was transient, lasting 1–3 days, and not associated with functional impairment. Shown here is grade 3
injection site swelling of the left shoulder of a study participant.
doi:10.1371/journal.pone.0009041.g002
Table 4. Signs and Solicited Symptoms during the 7-Day Follow-Up Periods after Each Immunization: All Dose Regimens of
Malaria Vaccine and Rabies Vaccine.
FMP2.1/AS02A Rabies vaccine
Immunization 1 Immunization 2 Immunization 3 Immunization 1 Immunization 2 Immunization 3
n=75 n=73 n=68 n=25 n=25 n=23
Overall Severe Overall Severe Overall Severe Overall Severe Overall Severe Overall Severe
n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Local
Pain (%) 43 (57.3) 3 (4.0) 41 (56.2) 0 31 (45.6) 0 2 (8.0) 0 4 (16.0) 0 1 (4.3) 0
Swelling (%) 51 (68.0) 49 (65.3) 51 (69.9) 51 (69.9) 49 (72.1) 48 (70.6) 6 (24.0) 5 (20.0) 4 (16.0) 4 (16.0) 3 (13.0) 3 (13.0)
Erythema (%) 0 0 0 0 1 (1.5) 1 (1.5) 0 0 0 0 0 0
General
Fever (%) 17 (22.7) 0 15 (20.5) 0 13 (19.1) 0 0 0 2 (8.0) 0 4 (17.4) 0
Drowsiness (%) 0 0 0 0 0 0 0 0 0 0 0 0
Irritability/Fussiness (%) 0 0 0 0 0 0 0 0 0 0 0 0
Loss of appetite (%) 3 (4.0) 0 2 (2.7) 0 0 0 0 0 0 0 0 0
Vomiting (%) 1 (1.3) 0 0 0 0 0 0 0 0 0 0 0
doi:10.1371/journal.pone.0009041.t004
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immunization. Laboratory abnormalities detected on days of
immunization were seen in blood samples that had been collected
just prior to immunization.
Other abnormal hematology (lymphocyte count) and biochem-
istry (serum creatinine and ALT) laboratory abnormalities were
evenly distributed among study groups. In addition to the 3 ALT
abnormalities constituting SAEs described above (1 in the 25 mg
group and 2 in the rabies vaccine group), 9 additional elevated
ALT values were reported; 2 in the 10 mg group, 2 in the 25 mg
group (1 attributed to hepatitis B); 4 in the 50 mg group (2
attributed to hepatitis A) and 1 in the rabies vaccine group
(attributed to hepatitis A). No temporal pattern relative to
immunizations was apparent in these cases of ALT elevation.
Immunogenicity
Baseline antibody levels were low in all groups (Figure 3).
Immunization with the 3 dose levels was followed by a dramatic
rise in anti-AMA1 antibodies, significantly higher than in the
control group after a single immunization. Antibody levels peaked
4 weeks after the third immunization on study day 90 with 100-
fold or greater rise relative to baseline, and remained significantly
higher than in the control group throughout the 12 months of the
study. In all groups the antibodies waned as the malaria
transmission season was ending and rose as the new malaria
season began. At all post-immunization time points, mean log
antibody levels (mg/mL) were significantly higher in the malaria
vaccine groups compared to the rabies vaccine group (t-test p-
values ,0.0001 at all post-immunization time points for each
malaria vaccine dose group compared to rabies vaccine group).
Longitudinal models showed the same results, with p-val-
ues,0.0001 at all post-immunization time points for each malaria
vaccine dose group compared to rabies vaccine. All doses of the
malaria vaccine induced similar high levels of antibodies, with
overlapping 95% confidence intervals among the 3 malaria vaccine
dose groups at all time points. Pre-immunization anti-AMA
antibody levels tended to be lower in children in the youngest
age group (1–2 years) than in older children (data not shown).
Discussion
Interpretation
This study is the first evaluation of the AMA1-based malaria
vaccine FMP2.1/AS02A in malaria-experienced children. The 3
dose levels of the malaria vaccine had acceptable tolerability.
Local reactions were more frequent in malaria vaccine groups
than in the comparator group. Pain and/or swelling at the
injection site were experienced by most recipients of the malaria
vaccine. Although swelling was often classified as grade 3 based on
the size of the reaction (.20 mm), these episodes of swelling were
short-lived and were usually unnoticed by participants (Figure 2).
Nine participants received fewer than 3 vaccine doses. Four SAEs
were observed; all were instances of grade 4 laboratory
abnormalities. A high follow-up rate (96%) was achieved.
All 3 dose levels of the malaria vaccine elicited high levels of
antibodies recognizing the vaccine antigen after a single
immunization, peaking a month after the third immunization.
The children in this trial had almost 30-fold lower baseline levels
of anti-AMA1 antibodies than adults had in a previous trial of this
Figure 3. Anti-AMA1 antibody levels. Geometric mean of antibodies (mg/mL) to homologous recombinant AMA1 for FMP2.1/AS02A 50 mg dose,
FMP2.1/AS02A 25 mg dose, FMP2.1/AS02A 10 mg dose and rabies vaccine recipients. Times of each of 3 immunizations are indicated by arrows. Error
bars represent 95 percent confidence intervals.
doi:10.1371/journal.pone.0009041.g003
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vaccine at this site [17], and this lower baseline likely accounts for
the more than 100-fold increase following immunization, com-
pared to a 5- to 6-fold rise in the adult trial. These high levels were
sustained for 1 year after the first dose was given. No significant
differences in antibody levels were observed between the malaria
vaccine groups.
The peak antibody levels reached a month after the third
immunization in these children were similar to, or even slightly
higher than, those seen previously in adults at this site. In adults we
observed a tendency toward a dose response, with the 50 mg group
having the highest antibody levels, while in children the 25 mg
antibody levels were slightly higher. None of these differences,
however, were statistically significant, and the proportions of
children with 4-fold or higher rises in antibody levels was similarly
high in all age groups and at all post-immunization time points
(data not shown), supporting the conclusion that there was no dose
effect. Since data on the duration of these responses were not
available at the time the Phase 2 trial began, the highest dose with
an acceptable safety profile, 50 mg, was selected for further
evaluation.
Generalizability
The safety and tolerability profile of the FMP2.1/AS02A
vaccine was similar to that seen in previous trials of this vaccine
in North American malaria-naı¨ve volunteers [16] and in Malian
adults [17], as well as in trials of a similar recombinant protein
blood-stage malaria vaccine with the same adjuvant in this and
other African populations [29,30]. As in these other trials, most of
the adverse reactions both to the malaria vaccine and to the rabies
vaccine were local and transient. There was no evidence of an
increased risk of anemia, a concern raised in the report of the
Phase 2 trial of the AMA1-C1 vaccine [20]
All 3 dose levels of the FMP2.1/AS02A vaccine resulted in at
least 100-fold increases in AMA1 antibody levels. While it is not
possible to compare antibody levels measured in this trial with
those seen in trials of other AMA1 vaccines, based on the relative
fold-rise and duration of antibody responses this profile compares
favorably with much lower and shorter-lived increases in antibody
levels observed in Malian children immunized with AMA1-C1, an
AMA1 vaccine adjuvanted with aluminum hydroxide [19], which
provided no measurable protection in a recently reported Phase 2
trial at another site in Mali. Notably, while baseline antibody levels
among children in this trial were about 10-fold to 50-fold lower
than pre-immunization levels in adults at this same site, children
achieved post-immunization AMA1 antibody levels that were at
least as high as those seen in vaccinated adults [17,20]. Moreover,
the post-immunization AMA1 antibody levels in children were
about 10-fold higher than baseline levels in semi-immune adults
who have robust naturally acquired immunity that protects them
against clinical malaria disease despite frequent infection.
Although the strong and sustained antibody responses observed
in this trial are encouraging, it is not known whether antibodies
raised against AMA1 based on the 3D7 clone of P. falciparum will
protect against infection with the highly diverse forms of AMA1
found in nature [9,13,15]. The AMA1 vaccine that recently failed
to demonstrate protection, AMA1-C1, is a bivalent vaccine based
on genetically diverse AMA1 sequences derived from two different
P. falciparum isolates. It is not yet known whether this lack of
efficacy is due to an insufficiently robust immune response, to
failure of allele-specific antibodies to protect against the wide array
of AMA1 variants, or because immune responses to AMA1 alone
are simply unable to prevent clinical malaria. High levels of
inhibitory AMA1 antibodies were correlated with protection in a
recent trial of AMA1 vaccines in Aotus monkeys [31], supporting
the idea that AMA1-C1 could have failed because it was
insufficiently immunogenic.
Previous studies have shown that the FMP2.1/AS02A vaccine
elicits antibodies that inhibit both parasite growth and AMA1
processing in homologous parasites [16] as well as measurable
cellular immune responses [22]. Post-immunization sera from
Malian adults who received the 50 mg dose of FMP2.1/AS02A
(but not sera from those who received the 25 mg dose) of the
malaria vaccine had significantly greater growth inhibition activity
against both 3D7 and FVO parasites than did post-immunization
sera from the rabies comparator group in the previous Phase 1
trial [17]. However, until an AMA1 malaria vaccine demonstrates
clinical efficacy against genetically diverse natural parasites, the
relevance of growth inhibition assays and other humoral and
cellular immunogenicity endpoints for clinical development
decisions will remain a matter of reasoned conjecture.
Overall Evidence
Based on its good safety profile, acceptable tolerability, and very
robust antibody responses, the 50 mg dose of the AMA1-based
malaria vaccine FMP2.1/AS02A was selected for evaluation in a
Phase 2 efficacy trial in children aged 1–6 years at the Bandiagara
Malaria Project in Mali. If the results of this trial are promising,
the development pathway for this vaccine could include
incorporating the FMP2.1 antigen as one component of a multi-
stage, multi-antigen malaria vaccine in combination with RTS,S
[8], improved adjuvant formulations [32] and/or separate
development as a disease-blocking vaccine for use in targeted
populations in malaria transmission areas. As AMA1 malaria
vaccines are evaluated in efficacy trials, the impact of genetic
diversity of parasite antigens on vaccine efficacy is likely to emerge
as a critical problem requiring integration of methods and
concepts drawn from molecular epidemiology, molecular evolu-
tion, immunology and structural vaccinology [9,13].
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